The patent examination expert group of the State Intellectual Property Office went to Nanjing Kati Medicine to conduct research
On October 12, the director of the Jiangsu Provincial Department of Biomedicine and the Director of the Biological Examination Office of the State Intellectual Property Office led a research team to Nanjing Kati to conduct special investigations on "standardizing the patent examination of immune cell therapy and promoting the high-quality development of the original pharmaceutical industry". The research team visited Katy Medicine and conducted research discussions with the senior management team.
The research team first visited the experimental area and, through the introduction of Dr. Wang Enxiu, the founder of Katy, detailed the company's development history and talent echelon. Dr. Wang Enxiu, the founder of Kati, pointed out that in the National Fourteenth Five-Year Plan, the strategic emerging industry status of the biomedical industry is clearly defined. The original innovative medicine industry is also one of the eight major industries supported by Nanjing. Kati has always shouldered the mission of precise treatment of solid tumors, actively integrated into the global innovation network in the field of immunotherapy, and strive to become a leading company in the industry, so that R&D results can benefit the general public. Ms. Xu Rong, Chief Operating Officer of Nanjing Katy Medical, introduced the park where Katy is located. There are several heavyweight immune cell therapy companies in Nanjing Biomedicine Valley. They focus on new drug research and development as the main field of research and strive to become a source of innovation in the pharmaceutical field. Platforms and companies provide customized services for scientific research transformation, clinical trials, and personnel training.
At the research seminar, Director Wu of the Biomedicine Department of the Jiangsu Center of the State Intellectual Property Office introduced that with the continuous release of favorable policies, the development of China's innovative drug industry has entered a "highlight moment", not only for the R&D and innovation capabilities of enterprises In order to standardize the patent review of immune cell therapy and promote the high-quality development of the original research pharmaceutical industry, it is urgent to sort out the standards and key points of patent review in the field of immune cell therapy.
